CLRB Cellectar Biosciences, Inc.
Price Chart
Executive Summary
Cellectar Biosciences filed Amendment No. 1 to its 2025 Form 10-K solely to add Part III information (directors, executive officers, security ownership, related transactions, and audit fees) that was previously omitted pending a proxy statement. No financial statements were amended, no restatements were made, and no changes were made to the original financial results or disclosures. This is a routine administrative filing with no material financial impact.
Actionable Insight
This filing contains no new financial information or material events. Monitor the upcoming proxy statement and any subsequent 8-Ks for updates on the iopofosine I 131 NDA timeline, which is the primary catalyst for this pre-revenue biotech.
Key Facts
- Amendment adds Part III Items 10, 12, 13, and 14 (director/officer info, beneficial ownership, related transactions, audit fees) that were omitted from the original 10-K filed March 4, 2026.
- No financial statements, no restatements, and no changes to any previously reported financial data.
- Auditor remains Deloitte & Touche LLP (Morristown, NJ). Audit fees declined from $1,883,941 in FY2024 to $878,391 in FY2025.
- As of April 29, 2026, there were 4,240,129 common shares outstanding. Directors and officers as a group beneficially own 4.68% of common stock.
- The company disclosed a prior restatement of FY2022 and FY2023 financials, with FY2024 audit fees including costs related to that restatement.
Financial Impact
No new financial data. Audit fees fell from $1,883,941 (FY2024) to $878,391 (FY2025).
Risk Factors
- Pre-revenue clinical-stage biotech with $11M market cap — high cash burn risk.
- Prior restatement of FY2022 and FY2023 financials indicates historical accounting control issues.
- Heavy reliance on iopofosine I 131 regulatory approval for any future value inflection.
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 10-K/A Filing (Primary) | 0001104659-26-053090 |
| Document: clrb-20251231xex31d2.htm | 0001104659-26-053090 |
| Document: clrb-20251231xex31d4.htm | 0001104659-26-053090 |
| Document: 0001104659-26-053090-index-headers.html | 0001104659-26-053090 |
| Document: 0001104659-26-053090-index.html | 0001104659-26-053090 |
| Document: 0001104659-26-053090.txt | 0001104659-26-053090 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 1, 2026
13d ago
|
Press Release
| $2.97 $2.59 | ▼ −12.79% | ▼ −10.04% | $2.23 (−24.92%) |
|
May 29, 2026
16d ago
|
S-1/A
| $3.14 $2.60 | ▲ +17.20% | ▲ +16.90% | $2.23 (+28.98%) |
|
May 28, 2026
17d ago
|
DEFA14A
| $3.14 $2.59 | ▼ −17.52% | ▼ −15.02% | $2.23 (−28.98%) |
|
May 19, 2026
26d ago
|
S-1
| $3.17 $3.14 | ▲ +0.95% | ▲ +2.18% | $2.23 (+29.65%) |
|
May 14, 2026
4w ago
|
8-K
| $3.20 $3.17 | ▼ −0.94% | ▼ −0.22% | $2.23 (−30.31%) |
|
May 14, 2026
4w ago
|
Press Release
| $3.20 $3.17 | ▼ −0.94% | ▼ −0.22% | $2.23 (−30.31%) |
|
May 11, 2026
4w ago
|
Press Release
| $3.06 $3.14 | ▲ +2.61% | ▲ +2.70% | $2.23 (−27.12%) |
|
May 8, 2026
5w ago
|
8-K
| $3.10 $3.20 | ▼ −3.23% | ▼ −1.76% | $2.23 (+28.06%) |
|
May 7, 2026
5w ago
|
Insider Cluster
| $3.30 $2.94 | ▲ +10.91% | ▲ +12.41% | $2.23 (+32.42%) |
|
May 6, 2026
5w ago
|
424B5
| $3.53 $2.92 | ▲ +17.28% | ▲ +18.41% | $2.23 (+36.83%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access